



Vinorelbine


9,000 compound screen on ID8 *Trp53*^{-/-} cells



**ID8 *Trp53*^{-/-}
cells**




Vinorelbine



Apoptosis



**High grade serous
ovarian carcinoma
murine model**



Vinorelbine



Survival benefit

Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma

Stephanie Drymiotou¹, Christophe J. Queval², Katherine E. Tyson³, Lesley A. Sheach^{1,†}, Antonio Postigo^{1,&}, Ilaria Dalla Rosa¹, Darren P. Ennis³, Michael Howell², Iain A. McNeish^{3*} and Michael Way^{1,4*}

¹Cellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.

²High Throughput Screening Laboratory, The Francis Crick Institute.

³Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, W12 0HS, UK

⁴Department of Infectious Disease, Imperial College London, SW7 2AZ, UK.

*Co-corresponding

[†]Current address: Department of Obstetrics & Gynaecology, Barts Health NHS Trust, London, E11 1NR, UK

[&]Current address: Stratosvir Limited, Stevenage, SG1 2FX, UK

Abstract

Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 (Δ VF) to induce death of ID8 *Trp53*^{-/-} murine ovarian cancer cells. We identified a class of tubulin polymerisation inhibitors including vinorelbine. The combination of vinorelbine and vaccinia induces ID8 *Trp53*^{-/-} cell death via apoptosis. In a syngeneic mouse model of high grade serous ovarian carcinoma, Δ VF virus lacking the viral thymidine kinase (TK), armed with GM-CSF and expressing NeonGreen (Δ VFTK-NG-GM-CSF) is tumour specific. A combination of the Δ VFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests that vinorelbine is a promising agent to combine with oncolytic vaccinia virus for the management of ovarian cancer.

Introduction

Ovarian cancer (OC) is the sixth most common female malignancy in the UK and the leading cause of death from a gynaecological cancer.¹ It is a highly heterogeneous disease with histotypes varying in their genetic and molecular profiles, clinical phenotypes and risk factors.² Despite its heterogeneity, standard management has remained the same for decades and includes surgical debulking combined with platinum-taxane chemotherapy.³ Response rates are initially high, especially in high grade serous carcinoma but 80% of patients with advanced disease recur, with all relapsed disease ultimately developing fatal therapy resistance.⁴ The introduction of bevacizumab (VEGF inhibitor) and PARP inhibitors in treatment regimens based on tumour molecular biomarker status can extend progression-free survival.^{5,6} However, the failure of maintenance therapies to extend overall survival for the majority of patients highlights the need for new therapies that overcome chemoresistance.^{7,8}

Vaccinia virus represents a promising oncolytic agent for OC due to its natural tropism for ovarian tissue.⁹ The virus is best known for its use as the vaccine for smallpox eradication in the 1980s, demonstrating its safety and tolerability in humans.¹⁰ It also preferentially infects, replicates and kills primary and metastatic tumours over normal tissues.^{11,12} This tumour-specific cytotoxicity reduces the systemic side effects induced by the virus compared to existing chemotherapeutics.¹³ It also exclusively replicates in the cytoplasm thus avoiding DNA insertions into the host genome.¹⁴ Moreover, the safety and tumour specificity of the virus has been further enhanced through genome manipulation, by deleting genes encoding for virulence factors and proteins regulating nucleotide metabolism.¹⁵ For example, loss of thymidine kinase (TK) and vaccinia growth factor (VGF) significantly reduces viral pathogenicity, reducing side effects in patients, while simultaneously increasing tumour specificity.^{16,17,18} Therefore, TK and VGF are deleted from most vaccinia strains used in clinical trials.¹⁹ Vaccinia can tolerate 25-40 kb foreign DNA insertions and transgenes have been expressed in non-essential loci to improve its oncolytic properties and immunogenicity.^{20,15} Vaccinia kill cells by direct oncolysis and induces immunogenic cell death, an attractive feature that can be exploited and enhanced when used as an oncolytic virus against OC tumours.^{21,22}

Olvi-Vec, derived from the Lister vaccinia strain, is the only oncolytic that has progressed to a phase III clinical trial for the treatment of platinum resistant OC in combination with chemotherapy and bevacizumab.^{23,24} This trial provided evidence that patients with

71 platinum-resistant disease can respond to platinum chemotherapy. In contrast, a phase II
72 clinical trial using the attenuated modified vaccinia Ankara virus expressing 5T4 tumour
73 associated antigen (MVA-5T4, Trovax) monotherapy in asymptomatic women with
74 recurrent ovarian cancer failed to show a significant improvement compared to placebo.²⁵
75 This trial highlights the importance of combination therapies for OC with vaccinia.

76
77 The **primary** aim of our study was to identify a combination regimen that enhances the
78 efficacy of vaccinia in treating ovarian carcinoma *in vivo*. We took advantage of a
79 recombinant vaccinia virus lacking F1, a viral inhibitor of apoptosis^{26,27} and the vaccinia
80 growth factor (VGF).^{28,29} The recombinant Δ VF virus induces increased cell death during
81 infection compared to the parental Western Reserve (WR).³⁰ This is the first study in
82 which the oncolytic efficacy of Δ VF was assessed *in vivo* in a syngeneic high grade serous
83 ovarian carcinoma mouse model. Additional recombinant viruses have been constructed
84 to improve the tumour specificity and immunogenicity of Δ VF. A high throughput
85 compound screen was also conducted to identify combination partners that enhance the
86 efficiency of Δ VF and its derivatives in killing ovarian cancer cells and inhibiting tumour
87 progression.

88 89 **Results**

90 **Targeting and arming Δ VF recombinant virus**

91 To improve the potential tumour specificity of the Δ VF virus, we deleted the thymidine
92 kinase (TK) gene to generate the Δ VFTK virus. To facilitate visualisation of infected cells,
93 we also introduced NeonGreen (NG) into the TK locus, generating the Δ VFTK-NG virus.
94 This virus was additionally armed with granulocyte-macrophage colony-stimulating factor
95 (GM-CSF) (Δ VFTK-NG-GM-CSF). **The inclusion of GM-CSF in this construct was not
96 intended for mechanistic investigation of its immunological effects. Rather, the overall aim
97 of this study was to identify small molecule inhibitors that enhance the antitumour efficacy
98 of the recombinant viruses, rather than to assess GM-CSF-mediated immune responses.**

99 Characterisation of the new recombinant viruses demonstrated they have similar viral
100 protein expression and spread profiles to the Δ VF virus (Figure 1A and B). Immunoblot
101 analysis confirmed NeonGreen (26 kDa) and the NeonGreen-GM-CSF fusion protein (47
102 kDa) were expressed in cells infected with the Δ VFTK-NG and Δ VFTK-NG-GM-CSF
103 viruses (Figure 1A). Moreover, all viruses retained the pro-apoptotic activity of the parental
104 Δ VF virus (Figure 1C).

The oncolytic efficacy of the new recombinant viruses was examined *in vivo* using a syngeneic mouse model of high grade serous ovarian carcinoma (ID8 *Trp53*^{-/-}) (Figure 2A). The heat inactivated ΔVF (ΔVFi) virus was used as vehicle and the median survival of mice in this group was 45.5 days. The median survival of mice inoculated with ΔVF, ΔVFTK, ΔVFTK-NG and ΔVFTK-NG-GM-CSF viruses was 51.5, 51, 51 and 54 days, respectively. Log-rank analysis demonstrated that only ΔVFTK-NG-GM-CSF (p = 0.005) significantly prolonged mouse survival (Figure 2B) compared to vehicle control. Viral inoculation of mice with the recombinant viruses had no effect on the size of their liver and spleen nor ascitic volumes (Figure 2C). NeonGreen expression did not affect mouse survival as mice inoculated with ΔVFTK and ΔVFTK-NG had the same median survival of 51 days. An additional survival experiment in which viral treatment began 14 days post intraperitoneal (IP) ID8 *Trp53*^{-/-} cell injection with the mice receiving four viral IP doses instead of three was conducted. In this protocol, both ΔVFTK-NG and ΔVFTK-NG-GM-CSF viruses significantly prolonged mouse survival compared to the heat inactivated ΔVF control (Figure S1). These data provide further support for the contribution of viral oncolysis to the observed therapeutic benefit and indicate that the ΔVFTK-NG-GM-CSF was the only recombinant virus that consistently improved survival. These experiments also illustrated the need to identify combination agents to improve the efficacy of vaccinia virus in the treatment of ovarian cancer.

Identifying a combination agent to improve the efficacy of oncolytic vaccinia

A high throughput drug screen was conducted on ΔVFTK-NG infected murine ovarian cancer (ID8 *Trp53*^{-/-}) cells (Figure 3A). The library consisted of 9,000 well-characterised compounds that are in clinical development or have been approved by Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) and used in clinic. NeonGreen fluorescence was used to identify infected cells and DAPI staining of nuclei was used to calculate the number of cells remaining at the end of the screen. After imaging of wells compounds were allocated into one of four categories ('no effect', 'kill infected cells', 'block virus replication' and 'toxic') based on the number of infected (green) and uninfected (non-green) cells relative to infected DMSO controls on the same plate (Figure 3B). The 'no effect' are wells with similar numbers of infected and uninfected cells compared to the DMSO control, whereas 'block virus replication' are those with reduced infected and increased uninfected cells due to cell proliferation. Toxic compounds resulted in a significant loss of infected and uninfected cells. The ideal compounds are the 'kill infected cells' category as they represent wells with fewer infected but similar numbers of

uninfected cells compared to the DMSO control (Figure 3C). These compounds are in principle enhancing the efficacy of vaccinia in killing infected ID8 *Trp53*^{-/-} cells.

Images from 'kill infected cells' wells were reviewed and a cut-off ratio of infected to uninfected cells of 0.3 was applied to generate the initial hit list of 60 compounds (Table 1). During the validation of these hits, an additional 60 compounds, absent from the initial library that belong to the same class of molecules and/or had a similar mechanism of action were added to the hit list (Figure S2). A secondary live-cell imaging screen was conducted to assess compound cytotoxicity as well as the impact on viral replication and spread. Based on this analysis, the compounds were categorised as 'kill infected cells', 'impair viral replication' and 'toxic' (Figure 3D). Positive hits ('kill infected cells') were identified based on the reduction in median percentage of infected cell confluency per well over time compared to uninfected cells. This analysis resulted in twenty compounds, seven of which are tubulin polymerisation inhibitors (Figure 3E). We decided to focus on the seven compounds targeting the same process as this is likely to be indicative of true hits. The impact of these inhibitors was further confirmed in two additional human high grade serous ovarian cancer cell lines, OVCAR3 and OVCAR4 (Figure S3 and S4).

Vinorelbine is a semi-synthetic second generation vinca alkaloid with a broad spectrum antitumour activity that inhibits microtubule assembly.^{31,32} It has reduced side effects including neurotoxicity compared to other vinca alkaloids.³³ An oral vinorelbine formulation is also available making it an appealing combination agent.³⁴ Vinorelbine is mainly used to treat non-small cell lung and breast cancers but also has some efficacy against ovarian cancer.^{35,36,37,38} Based on this, we selected vinorelbine for mechanistic exploration and *in vivo* experiments.

Vaccinia and vinorelbine induce ID8 *Trp53*^{-/-} cell death via apoptosis

Vinorelbine treatment of uninfected ID8 *Trp53*^{-/-} cells for 16 hours results in the loss of their characteristic cobblestone appearance and cell to cell contacts as well as some cell rounding, indicative of possible progression to cell death (Figure 4A). Immunofluorescence analysis confirmed that vinorelbine results in loss of microtubules in both ID8 *Trp53*^{-/-} cells with or without infection with the Δ VFTK virus (Figure 4B). Vinorelbine treatment also induced nuclear fragmentation and the formation of multinucleated cells suggestive of defects in cytokinesis or cell fusion.

[Click here to view linked References](#)

Vinorelbine enhances the efficacy of oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma

Stephanie Drymiotou¹, Christophe J. Queval², Katherine E. Tyson³, Lesley A. Sheach^{1,†}, Antonio Postigo^{1,&}, Ilaria Dalla Rosa¹, Darren P. Ennis³, Michael Howell², Iain A. McNeish^{3*} and Michael Way^{1,4*}

¹Cellular Signalling and Cytoskeletal Function Laboratory, The Francis Crick Institute, London, NW1 1AT, UK.

²High Throughput Screening Laboratory, The Francis Crick Institute.

³Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, W12 0HS, UK

⁴Department of Infectious Disease, Imperial College London, SW7 2AZ, UK.

*Co-corresponding

[†]Current address: Department of Obstetrics & Gynaecology, Barts Health NHS Trust, London, E11 1NR, UK

[&]Current address: Stratosvir Limited, Stevenage, SG1 2FX, UK

Abstract

Vaccinia virus, known for its clinical safety has a tropism for primary and metastatic tumours as well as ovarian tissue. Consequently, oncolytic approaches with recombinant vaccinia viruses have emerged as attractive agents against ovarian cancer. Unfortunately, oncolytic vaccinia monotherapies are yet to live up to their potential promise. Given this, there is a need to identify combination agents that improve the effectiveness of vaccinia in ovarian cancer treatment. We screened 9,000 compounds to identify drugs that enhance the ability of a recombinant vaccinia virus lacking VGF and F1 (Δ VF) to induce death of ID8 *Trp53*^{-/-} murine ovarian cancer cells. We identified a class of tubulin polymerisation inhibitors including vinorelbine. The combination of vinorelbine and vaccinia induces ID8 *Trp53*^{-/-} cell death via apoptosis. In a syngeneic mouse model of high grade serous ovarian carcinoma, Δ VF virus lacking the viral thymidine kinase (TK), armed with GM-CSF and expressing NeonGreen (Δ VFTK-NG-GM-CSF) is tumour specific. A combination of the Δ VFTK-NG-GM-CSF virus with vinorelbine prolongs mouse survival compared to the treatment of mice with either agent alone. Our study suggests that vinorelbine is a promising agent to combine with oncolytic vaccinia virus for the management of ovarian cancer.

Introduction

Ovarian cancer (OC) is the sixth most common female malignancy in the UK and the leading cause of death from a gynaecological cancer.¹ It is a highly heterogeneous disease with histotypes varying in their genetic and molecular profiles, clinical phenotypes and risk factors.² Despite its heterogeneity, standard management has remained the same for decades and includes surgical debulking combined with platinum-taxane chemotherapy.³ Response rates are initially high, especially in high grade serous carcinoma but 80% of patients with advanced disease recur, with all relapsed disease ultimately developing fatal therapy resistance.⁴ The introduction of bevacizumab (VEGF inhibitor) and PARP inhibitors in treatment regimens based on tumour molecular biomarker status can extend progression-free survival.^{5,6} However, the failure of maintenance therapies to extend overall survival for the majority of patients highlights the need for new therapies that overcome chemoresistance.^{7,8}

Vaccinia virus represents a promising oncolytic agent for OC due to its natural tropism for ovarian tissue.⁹ The virus is best known for its use as the vaccine for smallpox eradication in the 1980s, demonstrating its safety and tolerability in humans.¹⁰ It also preferentially infects, replicates and kills primary and metastatic tumours over normal tissues.^{11,12} This tumour-specific cytotoxicity reduces the systemic side effects induced by the virus compared to existing chemotherapeutics.¹³ It also exclusively replicates in the cytoplasm thus avoiding DNA insertions into the host genome.¹⁴ Moreover, the safety and tumour specificity of the virus has been further enhanced through genome manipulation, by deleting genes encoding for virulence factors and proteins regulating nucleotide metabolism.¹⁵ For example, loss of thymidine kinase (TK) and vaccinia growth factor (VGF) significantly reduces viral pathogenicity, reducing side effects in patients, while simultaneously increasing tumour specificity.^{16,17,18} Therefore, TK and VGF are deleted from most vaccinia strains used in clinical trials.¹⁹ Vaccinia can tolerate 25-40 kb foreign DNA insertions and transgenes have been expressed in non-essential loci to improve its oncolytic properties and immunogenicity.^{20,15} Vaccinia kill cells by direct oncolysis and induces immunogenic cell death, an attractive feature that can be exploited and enhanced when used as an oncolytic virus against OC tumours.^{21,22}

Olvi-Vec, derived from the Lister vaccinia strain, is the only oncolytic that has progressed to a phase III clinical trial for the treatment of platinum resistant OC in combination with chemotherapy and bevacizumab.^{23,24} This trial provided evidence that patients with

71 platinum-resistant disease can respond to platinum chemotherapy. In contrast, a phase II
72 clinical trial using the attenuated modified vaccinia Ankara virus expressing 5T4 tumour
73 associated antigen (MVA-5T4, Trovax) monotherapy in asymptomatic women with
74 recurrent ovarian cancer failed to show a significant improvement compared to placebo.²⁵
75 This trial highlights the importance of combination therapies for OC with vaccinia.

76
77 The primary aim of our study was to identify a combination regimen that enhances the
78 efficacy of vaccinia in treating ovarian carcinoma *in vivo*. We took advantage of a
79 recombinant vaccinia virus lacking F1, a viral inhibitor of apoptosis ^{26,27} and the vaccinia
80 growth factor (VGF).^{28,29} The recombinant Δ VF virus induces increased cell death during
81 infection compared to the parental Western Reserve (WR).³⁰ This is the first study in
82 which the oncolytic efficacy of Δ VF was assessed *in vivo* in a syngeneic high grade serous
83 ovarian carcinoma mouse model. Additional recombinant viruses have been constructed
84 to improve the tumour specificity and immunogenicity of Δ VF. A high throughput
85 compound screen was also conducted to identify combination partners that enhance the
86 efficiency of Δ VF and its derivatives in killing ovarian cancer cells and inhibiting tumour
87 progression.

88 89 **Results**

90 **Targeting and arming Δ VF recombinant virus**

91 To improve the potential tumour specificity of the Δ VF virus, we deleted the thymidine
92 kinase (TK) gene to generate the Δ VFTK virus. To facilitate visualisation of infected cells,
93 we also introduced NeonGreen (NG) into the TK locus, generating the Δ VFTK-NG virus.
94 This virus was additionally armed with granulocyte-macrophage colony-stimulating factor
95 (GM-CSF) (Δ VFTK-NG-GM-CSF). The inclusion of GM-CSF in this construct was not
96 intended for mechanistic investigation of its immunological effects. Rather, the overall aim
97 of this study was to identify small molecule inhibitors that enhance the antitumour efficacy
98 of the recombinant viruses, rather than to assess GM-CSF-mediated immune responses.
99 Characterisation of the new recombinant viruses demonstrated they have similar viral
100 protein expression and spread profiles to the Δ VF virus (Figure 1A and B). Immunoblot
101 analysis confirmed NeonGreen (26 kDa) and the NeonGreen-GM-CSF fusion protein (47
102 kDa) were expressed in cells infected with the Δ VFTK-NG and Δ VFTK-NG-GM-CSF
103 viruses (Figure 1A). Moreover, all viruses retained the pro-apoptotic activity of the parental
104 Δ VF virus (Figure 1C).

The oncolytic efficacy of the new recombinant viruses was examined *in vivo* using a syngeneic mouse model of high grade serous ovarian carcinoma (ID8 *Trp53*^{-/-}) (Figure 2A). The heat inactivated ΔVF (ΔVFi) virus was used as vehicle and the median survival of mice in this group was 45.5 days. The median survival of mice inoculated with ΔVF, ΔVFTK, ΔVFTK-NG and ΔVFTK-NG-GM-CSF viruses was 51.5, 51, 51 and 54 days, respectively. Log-rank analysis demonstrated that only ΔVFTK-NG-GM-CSF (*p* = 0.005) significantly prolonged mouse survival (Figure 2B) compared to vehicle control. Viral inoculation of mice with the recombinant viruses had no effect on the size of their liver and spleen nor ascitic volumes (Figure 2C). NeonGreen expression did not affect mouse survival as mice inoculated with ΔVFTK and ΔVFTK-NG had the same median survival of 51 days. An additional survival experiment in which viral treatment began 14 days post intraperitoneal (IP) ID8 *Trp53*^{-/-} cell injection with the mice receiving four viral IP doses instead of three was conducted. In this protocol, both ΔVFTK-NG and ΔVFTK-NG-GM-CSF viruses significantly prolonged mouse survival compared to the heat inactivated ΔVF control (Figure S1). These data provide further support for the contribution of viral oncolysis to the observed therapeutic benefit and indicate that the ΔVFTK-NG-GM-CSF was the only recombinant virus that consistently improved survival. These experiments also illustrated the need to identify combination agents to improve the efficacy of vaccinia virus in the treatment of ovarian cancer.

Identifying a combination agent to improve the efficacy of oncolytic vaccinia

A high throughput drug screen was conducted on ΔVFTK-NG infected murine ovarian cancer (ID8 *Trp53*^{-/-}) cells (Figure 3A). The library consisted of 9,000 well-characterised compounds that are in clinical development or have been approved by Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) and used in clinic. NeonGreen fluorescence was used to identify infected cells and DAPI staining of nuclei was used to calculate the number of cells remaining at the end of the screen. After imaging of wells compounds were allocated into one of four categories ('no effect', 'kill infected cells', 'block virus replication' and 'toxic') based on the number of infected (green) and uninfected (non-green) cells relative to infected DMSO controls on the same plate (Figure 3B). The 'no effect' are wells with similar numbers of infected and uninfected cells compared to the DMSO control, whereas 'block virus replication' are those with reduced infected and increased uninfected cells due to cell proliferation. Toxic compounds resulted in a significant loss of infected and uninfected cells. The ideal compounds are the 'kill infected cells' category as they represent wells with fewer infected but similar numbers of

uninfected cells compared to the DMSO control (Figure 3C). These compounds are in principle enhancing the efficacy of vaccinia in killing infected ID8 *Trp53*^{-/-} cells.

Images from 'kill infected cells' wells were reviewed and a cut-off ratio of infected to uninfected cells of 0.3 was applied to generate the initial hit list of 60 compounds (Table 1). During the validation of these hits, an additional 60 compounds, absent from the initial library that belong to the same class of molecules and/or had a similar mechanism of action were added to the hit list (Figure S2). A secondary live-cell imaging screen was conducted to assess compound cytotoxicity as well as the impact on viral replication and spread. Based on this analysis, the compounds were categorised as 'kill infected cells', 'impair viral replication' and 'toxic' (Figure 3D). Positive hits ('kill infected cells') were identified based on the reduction in median percentage of infected cell confluency per well over time compared to uninfected cells. This analysis resulted in twenty compounds, seven of which are tubulin polymerisation inhibitors (Figure 3E). We decided to focus on the seven compounds targeting the same process as this is likely to be indicative of true hits. The impact of these inhibitors was further confirmed in two additional human high grade serous ovarian cancer cell lines, OVCAR3 and OVCAR4 (Figure S3 and S4).

Vinorelbine is a semi-synthetic second generation vinca alkaloid with a broad spectrum antitumour activity that inhibits microtubule assembly.^{31,32} It has reduced side effects including neurotoxicity compared to other vinca alkaloids.³³ An oral vinorelbine formulation is also available making it an appealing combination agent.³⁴ Vinorelbine is mainly used to treat non-small cell lung and breast cancers but also has some efficacy against ovarian cancer.^{35,36,37,38} Based on this, we selected vinorelbine for mechanistic exploration and *in vivo* experiments.

Vaccinia and vinorelbine induce ID8 *Trp53*^{-/-} cell death via apoptosis

Vinorelbine treatment of uninfected ID8 *Trp53*^{-/-} cells for 16 hours results in the loss of their characteristic cobblestone appearance and cell to cell contacts as well as some cell rounding, indicative of possible progression to cell death (Figure 4A). Immunofluorescence analysis confirmed that vinorelbine results in loss of microtubules in both ID8 *Trp53*^{-/-} cells with or without infection with the Δ VFTK virus (Figure 4B). Vinorelbine treatment also induced nuclear fragmentation and the formation of multinucleated cells suggestive of defects in cytokinesis or cell fusion.

Vaccinia hijacks the microtubule cytoskeleton to facilitate its replication, intracellular transport and spread.^{39,40,41,42} We previously found that depolymerization of microtubules with nocodazole reduces virus yield.⁴³ Consistent with this, immunoblot analysis revealed that vinorelbine treatment reduced both early (F12) and late (F13) viral protein expression, as well as H5, which is required for viral replication (Figure 4C). Vinorelbine treatment prior to infection of ID8 *Trp53*^{-/-} cells clearly impairs viral gene expression but it is not immediately obvious why there is enhanced cell death or which programmed cell death pathway (autophagy, necroptosis or apoptosis) is activated.

To assess whether vinorelbine induces autophagy in ID8 *Trp53*^{-/-} infected with the Δ VFTK-NG virus, we performed immunoblot analysis to examine the level of p62 expression and LC3 lipidation (LC3-II) (Figure 4D). In contrast to chloroquine treated cells (positive control), there was no change in the level of p62 in infected or non-infected cells with or without vinorelbine. Likewise, the levels of LC3-II did not change, except in the positive control indicating that autophagy is not responsible for increasing cell death of vinorelbine treated ID8 *Trp53*^{-/-} cells.

To investigate the possible involvement of necroptosis, we performed immunoblot analysis to examine the level of MLKL phosphorylation (pMLKL) and look for the presence of 50 kDa PARP fragment generated by lysosomal proteases.⁴⁴ We found pMLKL and the 50 kDa PARP fragment which are indicative of necroptosis are only present in the positive control (0.1% hydrogen peroxide and Z-VAD treatment) (Figure 4E). We did, however, see that vinorelbine induced cleavage of PARP to generate an 89 kDa fragment in infected cells, suggesting that apoptosis is responsible for their death.⁴⁵ The presence of cleaved caspase 3 and 8 in immunoblots of infected cells treated with vinorelbine confirmed apoptosis was activated (Figure 4F). The combination of vinorelbine and infection is required to induce apoptosis as PARP, caspase 3 or 8 cleavage is not observed in non-infected or infected cells with or without the drug respectively. Pre-treating infected cells with vinorelbine also appears to be more effective at inducing PARP, caspase 3 or 8 cleavage (Figure 4F). To examine if this translates into increased cell death, we performed live cell imaging of ID8 *Trp53*^{-/-} cells treated with vinorelbine before or after vaccinia infection using the same conditions used in the initial drug screen. We found that pre-treating ID8 *Trp53*^{-/-} cells with vinorelbine leads to increased initial cell death compared to adding vinorelbine after infection (Figure 4G). However, both conditions eventually result in similar levels of cell death.

Vinorelbine and ΔVFTK-NG-GM-CSF improves mouse survival

An *in vivo* distribution study was carried out to examine the tumour specificity of the ΔVFTK-NG-GM-CSF virus (Figure 5A). The ΔVFTK-NG-GM-CSF virus was selected for the combination studies with vinorelbine based on previous *in vivo* data showing that it was the only virus to consistently confer a survival benefit compared to the heat-inactivated virus. However, the role of GM-CSF transgene was not the focus of this investigation. Viral replication was detected in omental tumours but not in liver or spleen in mice inoculated intraperitoneally with virus with or without vinorelbine (Figures 5B and C). Pre-treatment with vinorelbine impacted viral replication *in vivo* consistent with our observations in ID8 *Trp53*^{-/-} cells in culture (Figures 5B and D). Vinorelbine also reduced the level of GM-CSF expression in omental tumours (Figure S5). To assess the efficacy of the combination treatment on the survival of mice we treated mice with vinorelbine 24 hours before injection of the ΔVFTK-NG-GM-CSF virus (Figure 5E). Log-rank analysis demonstrated that this combination significantly prolonged mouse survival compared to vinorelbine ($p=0.022$; median survival 73.5 vs 69 days) (Figure 5F). Moreover, both conditions were also significantly better than virus alone (median 57 days). Our observations suggest that combining vinorelbine and ΔVFTK-NG-GM-CSF virus improves mouse survival against high grade serous ovarian carcinomas.

Discussion

Vaccinia virus has the promise of being an ideal oncolytic agent given its safety profile and ability to be genetically enhanced as well as combined with drug treatments.^{46,47} Clinical trials frequently use viruses deleted of genes encoding VGF (ΔVGF) and/or the thymidine kinase (ΔTK) as this increases their tumour specificity and safety.^{48,17} Deletion of F1, an inhibitor of apoptosis in combination with TK also improves the oncolytic effectiveness of the virus as it extends mouse survival in a human glioblastoma model and delays tumour growth in a syngeneic mouse colon model.^{26,27,49} Based on the available evidence, a virus lacking VGF, TK and F1 is predicted to be safer and induce more tumour cell death.

We have now deleted VGF, TK and F1 in the Western reserve (WR) strain of Vaccinia and also inserted GM-CSF to the genome to increase the immunogenicity of the virus.

NeonGreen was also added which like other reporters, can be used to monitor viral replication, distribution, detect metastatic disease and assess toxicity clinically.^{50,51} Our *in vivo* survival studies demonstrated that our new recombinant viruses were well tolerated in mice bearing ID8 *Trp53*^{-/-} omental tumours but that only the Δ VFTK-NG-GM-CSF virus had consistently significant survival benefit (Figure 2B and S1). Moreover, when injected intraperitoneally the Δ VFTK-NG-GM-CSF virus specifically replicates in omental tumours but not in the liver or spleen (Figure 5A-C).

Multiple early phase clinical trials demonstrate that even with genomic modifications that enhance its tumour specificity, oncolytic activity and immunogenicity, vaccinia clearly still needs a combination agent to achieve its full oncolytic potential.^{25,46} Given this, we performed a high throughput drug screen on ID8 *Trp53*^{-/-} cells using 9,000 well-characterised compounds to identify those that increased the killing efficiency of our triple deleted recombinant virus. By performing primary and secondary drug screens, we identified 20 hit compounds, seven of which were tubulin polymerisation inhibitors (Figure 3E). Vinorelbine was our drug screen hit compound of choice given it has some activity against ovarian cancer.^{35,36,37}

We found that the combination of vaccinia with vinorelbine induces ID8 *Trp53*^{-/-} cell death via apoptosis. This is not unexpected, as the Δ VFTK-NG virus lacks F1 the main inhibitor of intrinsic apoptosis during infection.^{26,27} Vinca alkaloids such as vinorelbine also induce apoptosis, which is often attributed to impaired spindle formation and subsequent prolonged mitotic arrest.^{52,53} However, these chemotherapeutics can additionally stimulate apoptosis independently of the cell cycle via alternative mechanisms including the activation of intrinsic apoptosis.⁵⁴ Microtubule targeting agents have been shown to upregulate pro-apoptotic Bcl-2 proteins (BAX, BAK, PUMA, Noxa and Bad) as well as inactivate anti-apoptotic Bcl-2 proteins through phosphorylation (Bcl-2, Bcl-xL, Mcl-1, Bcl-W).^{53,55,56} Vinorelbine and the Δ VFTK-NG virus both act on the intrinsic mitochondrial apoptotic pathway and their effects complement each other leading to enhanced apoptotic cell death compared to either agent alone. Therefore, vinorelbine pre-treatment will not only induce mitotic arrest but also activate BAK/BAX leading to mitochondrial membrane pore formation resulting in a pro-apoptotic 'priming' making cells more susceptible to vaccinia induced apoptosis.⁵⁷ Consistent with this notion, vinorelbine pre-treatment of cells resulted in increased PARP and caspase cleavage at 24 hours post infection compared to adding the drug after infection (Figure 4F). Live-cell imaging also

demonstrated that addition of vinorelbine before infection increased initial cell death compared to first adding the virus and then the drug (Figure 4G).

When tested in a mouse model of high grade serous ovarian carcinoma, we found that the combination of vinorelbine followed by infection with the Δ VFTK-NG-GM-CSF virus produced a significant survival benefit compared to the control (median survival of 73.5 compared to 47.5 days). Our results are in line with previous studies demonstrating that a combination of vinorelbine and vesicular stomatitis virus (VSV) significantly prolonged the survival of aggressive subcutaneous 4T1 syngeneic mouse model of triple negative breast cancer.⁵⁸ Vinorelbine has good response rates in phase I and II clinical trials for recurrent ovarian cancer and the National Comprehensive Cancer Network recommended vinorelbine for recurrent epithelial, fallopian tube or primary peritoneal cancers.⁵⁹ It is evident from our *in vivo* experiments that vinorelbine at the dose used (4mg/kg) has good efficacy against ID8 *Trp53*^{-/-} tumours, suggesting that the drug represents a promising therapy for patients with high grade serous carcinoma. Nevertheless, when vinorelbine is combined with the Δ VFTK-NG-GM-CSF virus mouse survival is further increased.

Our findings suggest that the enhanced tumour cell killing observed with the combination of vinorelbine and Δ VFTK-NG-GM-CSF is primarily due to an additive or synthetic lethal interaction, rather than increased viral replication. Although vinorelbine initially suppressed cell proliferation *in vitro*, confluency recovered over time, indicating a predominantly cytostatic effect (Figure 4G). In contrast, the combination treatment led to a sustained reduction in confluency, consistent with induction of apoptosis as confirmed by cleaved caspase-3 and PARP immunoblotting (Figure 4F and G). Moreover, qPCR analysis of viral gene expression demonstrated that vinorelbine pre-treatment reduced viral replication relative to infection with virus followed by vinorelbine, demonstrating that vinorelbine impairs vaccinia replication when administered prior to viral infection. These data support the notion that the combination effect arises from enhanced cell death rather than increased viral propagation.

Further experiments are required to examine the impact on mouse survival of reducing the number of doses and concentration of vinorelbine together with higher viral titres. In this way it should be possible to develop strategies with the Δ VFTK-NG-GM-CSF virus that are effective with lower vinorelbine doses to decrease systemic toxicity and the likelihood of patients becoming resistant to vinorelbine. In addition, adjusting the interval

between viral and vinorelbine administration may allow greater viral replication and transgene expression, potentially improving therapeutic efficacy. A limitation of the present study is that the immunological effects of the GM-CSF-expressing oncolytic vaccinia virus were not investigated. While GM-CSF is known to modulate anti-tumour immunity, dissecting its contribution in our system would require extensive *in vivo* and immunological studies, which are beyond the scope of the current work. Our primary aim was to perform a drug screen to identify compounds that enhance the efficacy of the recombinant oncolytic vaccinia virus. GM-CSF expression was attenuated in the presence of vinorelbine and although even low levels of GM-CSF might influence the tumour immune microenvironment, the combination efficacy observed here was not attributed to GM-CSF specifically. The immunomodulatory role of GM-CSF will be the subject of future studies directly comparing armed and unarmed viruses with vinorelbine. These studies should also include immune profiling of tumour-infiltrating dendritic cells, CD8⁺ T cells, and other relevant immune populations to clarify the role of GM-CSF in shaping therapeutic response. Future studies will also focus on validating these findings across additional syngeneic and human ovarian cancer models to assess the robustness and generalizability of the therapeutic effect.

Materials and methods

Cells and culture

The ID8 *Trp53*^{-/-} cell line was provided by Professor Iain McNeish, Imperial College London (London, UK).⁶⁰ HeLa and BS-C-1 cell lines were provided by the European Molecular Biology Laboratory (Heidelberg, Germany) and 143B TK^{-/-} from The Francis Crick Institute Cell Services (London, UK). All cell lines were mycoplasma tested and maintained in Dulbecco's Modified Eagle's Medium (DMEM) (Sigma-Aldrich, St. Louis, Missouri, #51435C) supplemented with 10% fetal bovine serum (FBS) (Thermo Fisher Scientific, Waltham, Massachusetts, #10270-106) and 1% penicillin/ streptomycin (pen/strep) (Sigma-Aldrich, #P4333) at 37°C and 5% CO₂.

Virus amplification and sucrose purification

HeLa cells were grown in 15 cm culture dishes (Corning Inc., Sigma Aldrich, #353025) at approximately 80% confluency and were infected with vaccinia at a MOI of 0.1 for 48-72 hours. The cells were scraped in PBS and centrifuged at 500 x g at 4°C for five minutes. Cell pellets were resuspended in PBS and re-centrifuged. The resulting cell pellet was

resuspended in 7 ml of Tris buffer (10 mM Tris HCl, 2 mM MgCl₂, pH 9.0), disrupted by 20 strokes in a 7 ml Wheaton Dounce homogenizer (DWK Life Sciences, Millville, New Jersey, #357538) and centrifuged at 500 x g at 4°C for five minutes. The supernatant was collected and added on top of an 8 ml 35% sucrose cushion in a Beckman SW40 ultracentrifuge tube (Beckman Coulter, Brea, California #3117-0380). The solution was centrifuged at 192, 000 x g at 4°C for 30 minutes in a Beckman Optima I-100 XP ultracentrifuge, using an SW32Ti swing-out rotor. The virus pellet was resuspended in a desired amount of Tris buffer, titrated using plaque assays, aliquoted and stored at -20°C (short term) or -80°C (long term).

Viral plaque assays and heat inactivation

Confluent monolayers of BS-C-1 cells were infected with vaccinia virus in serum free media at the required dilutions for one hour at 37°C, 5% CO₂. The media was then replaced with 2 ml of semi-solid media (1:1 ratio of 3% Carboxy-methyl cellulose sodium salt dissolved in water and 2X Modified Eagle's Medium (MEM) supplemented with 10% FBS and 1% pen/ strep). After 72 hours, the cells were fixed by adding 1 ml of 8% formaldehyde to the media for 30 minutes at room temperature. The media and formaldehyde were removed, and cells were stained with 1 ml crystal violet (1:5 dilution in Phosphate buffered saline [PBS]) for 30 minutes. Subsequently, the plates were rinsed with cold water and left to air dry. To determine the plaque size, plaque diameter was measured in mm using Fiji line tool, available at imagej.net. For heat inactivation, aliquots of viruses were incubated for three hours at 60°C and then cooled on ice for one hour. Heat inactivation was confirmed by the absence of plaque forming units using plaque assays.

Generation of recombinant viruses

Recombinant viruses were constructed in the Δ VF virus background which is derived from the Western Reserve (WR) strain.³⁰ The transient dominant selection (TDS) method was used to delete TK from the Δ VF genome.^{61,62} To create the targeting vector for TDS a DNA fragment containing the left (387bp) and right (321bp) TK recombination arms was cloned into the pSSGB vector containing the selectable markers GFP-*bsd* under the control of a synthetic vaccinia promoter (pSS) .⁶² The fluorescent Δ VFTK virus expressing NG (Δ VFTK-NG) and the Δ VFTK virus expressing NG and GM-CSF (Δ VFTK-NG-GM-CSF) under the control of the synthetic early/late vaccinia promoter (pEL) at the TK locus were created via homologous recombination between Δ VF virus and the pBS Δ TK-NG and

pBSΔTK-NG-GM-CSF targeting vectors, respectively. These targeting vectors were created using BlueScript (PBS(+)) as the backbone vector and DNA fragments containing sequences for pEL-NG and pEL-NG-GM-CSF as the inserts. For all new recombinant viruses, the targeting vectors contained TK recombination arms flanking the DNA sequence to be inserted in the vaccinia genome. A small portion of the 5' open reading frame of J2R (gene encoding for TK) was retained within the left TK recombination arm to ensure the correct transcription of J1R. These DNA fragments were synthesised using the IDT gBlocks gene synthesis service (Coralville, Iowa). Subsequently, HeLa cells, infected with ΔVF at MOI of 0.05 were transfected with the relevant targeting vectors using Lipofectamine 2000 (Thermo Fisher Scientific, #52887) and incubated for 48 hours at 37°C and 5% CO₂. The viruses were harvested by scraping the cells and subjecting them to three freeze-thaw cycles. The harvested viruses were used to infect confluent monolayers of 143B TK^{-/-} cells with BrdU selection or BS-C-1 cells with or without blasticidin selection. Recombinant viruses, which are shown schematically in Figure S6, were isolated by identifying and picking fluorescent green plaques over at least three rounds of purification. For all three recombinant viruses, TK deletion and/or insertions of NG or NG-GM-CSF were confirmed by PCR analysis after each round of plaque purification and sequencing. The recombinant viruses were amplified and purified using a 35% sucrose gradient.

Quantification of viral DNA and GM-CSF mRNA

Total DNA was isolated from mouse tissues using DNeasy Blood and Tissue Kit (QIAGEN, Hilden, Germany), as per manufacturer's protocol and quantified using a NanoDrop (Thermo Fisher Scientific). Real-time quantitative PCR (qPCR) was performed in triplicates in 384-well reaction plates (Applied Biosystems, Waltham, Massachusetts). Each PCR reaction (total volume 10 μl) contained 20 ng DNA, 5 μl Power SYBR-Green PCR Master Mix (Applied Biosystems) and 0.5 μM of forward and reverse primers. Viral DNA was amplified using primers specific to a region for H5 vaccinia gene (H5-F: 5'-GTAAGAAGTAAATGCGTGC-3', H5-R: 5'-CCACGTTTGTTCATATACTAC-3') and APP1 (APP1-F: 5'-CGGAAACGACGCTCTCATG-3' and APP1-R: 5'-CCAGGCTGAATTCCCCAT-3) was amplified as a nuclear gene standard reference. Changes in viral DNA amount were calculated using the 2^{-ΔΔCt} method and represented as fold changes relative to the indicated control.⁶³ For quantification of GM-CSF mRNA, 20 mg of omental tumour tissue was homogenised in TRIzol reagent using a Precellys Evolution tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France).

Following chloroform addition and centrifugation, the aqueous phase containing RNA was combined with an equal volume of 70% ethanol and purified using RNeasy Mini Kit columns, according to the manufacturer's instructions (QIAGEN). One-step quantitative RT-PCR was then performed on 50 µg of RNA template using the QuantiNova® SYBR® Green RT-PCR Kit (QIAGEN) with 0.5 µM of gene-specific primers: GM-CSF (Csf2-F: CTACTACCAGACATACTGCC; Csf2-R: GCATTCAAAGGGGATATCAG) and GAPDH as the housekeeping control (GAPDH-F: TCTTGTGCAGTGCCAGCCT; GAPDH-R: CAATATGGCCAAATCCGTTCA).

Immunoblotting

Cells were collected and lysed in 21 µl of PBS supplemented with Protease/ Phosphatase inhibitors (Cell Signalling, #5871) and 5U benzonase nuclease (Millipore, #E1014). SDS was added at a final concentration of 1% followed by 22 µl of 2X SDS loading buffer (Thermo Fisher Scientific, #LC2676). The samples were heated at 95°C for three minutes, loaded onto Bolt 4-12% or 10% Bis-Tris Plus pre-cast gels (Thermo Fisher Scientific) and run in MOPS SDS running buffer (Thermo Fischer Scientific, #NP0001) for 55 minutes at 150 V. SeeBluePlus2 protein standard (Thermo Fisher Scientific, #LC5925) was used as reference for protein molecular weight. The proteins were transferred to nitrocellulose membranes (Thermo Fischer Scientific, #IB23001), blocked in 5% milk in PBS with 0.1% Tween20 (PBS-T) (Sigma-Aldrich, #P9416) for one hour at room temperature and incubated overnight with primary antibodies. Primary antibodies used were: F12 (1:4,000, ⁶⁴), F13 (1:6,000, ³⁹), H5 (1:10,000, ⁶⁵), GRB2 (1:1,000, Santa Cruz, Dallas, Texas, #sc-255), Vinculin (1:10,000, Sigma-Aldrich, #V9264), GAPDH (1:1,000, Santa Cruz, #sc-32233), PARP (1:1,000, Cell Signalling, Danvers, Massachusetts, #9542), cleaved caspase 8 (1:1,000, Cell Signalling, #8592), cleaved caspase 3 (1:1,000, Cell Signalling, #9664), LC3-B (1:1,000, Abcam [#ab48394], Cambridge, UK), p62/SQSTM1 (1:1,000, Novus Biologicals, Centennial, Colorado, #NBP1-42822) and NeonGreen (1:1,000, Cell Signalling, #41236). Goat anti-rabbit (#111035003) and anti-mouse (#115005003) secondary HRP antibodies, obtained from Jackson ImmunoResearch (West Grove, Pennsylvania), were used at 1:10,000 in 5% milk with PBS-T. For the examination of phosphorylated proteins, 1 mM orthovanadate (New England Biolabs, Ipswich, Massachusetts, #P0758) was added during blocking, primary and secondary antibody incubation. The membranes were incubated with SuperSignal West Pico PLUS Chemiluminescence reagent (Thermo Fischer Scientific, #34580) for one minute at room temperature and exposed to UltraCruz Autoradiography Film (Santa Cruz, #sc-201697).

Drug screen

Chemical library

A small molecule drug library of 9,000 well-characterised compounds, assembled from commercial libraries by the High Throughput Screening (HTS) science technology platform (STP) of the Francis Crick Institute was used for the primary screen. This chemical library can be accessed (<https://hts.crick.ac.uk/db/view/libraryView.php>) under the database name: 'Full Chemical Collection V6'. A customised library of 120 compounds was purchased from MedChemExpress (Monmouth Junction, New Jersey) for the secondary screen.

Primary screen

The small molecule library, resuspended in dimethyl sulfoxide (DMSO), was transferred into intermediate Low Dead Volume (LDV; Labcyte, #LPS-0200) 384-well plates at a concentration of 10 and 1 mM. An acoustic liquid handler (Echo 550 Beckman-Coulter) was then used to dispense compounds into Greiner microclear 384-well plates (Greiner, #781091) so they reach a final concentration of 0.1, 1 and 10 μ M. Each assay plate was prepared in triplicate. Prior to cell seeding, the compounds were diluted in 10 μ l of complete DMEM per well. A volume of 40 μ l of cells, corresponding to 3,000 cells, was dispensed into the 384-well assay plates, which were incubated for 16 hours at 5% CO₂ and 37°C. The Δ VFTK-NG virus was dispensed in each well at an MOI 0.5 and the plates were incubated at 5% CO₂ and 37°C for 30 hours. Cells were fixed using 4% paraformaldehyde (PFA), permeabilised and stained by adding 0.01% Triton X-100 and DAPI. The cells were imaged on Opera Phenix[®] Plus (Revvity, Waltham, Massachusetts) using 10x air NA 0.3 objective. The microscope was equipped with a set of lasers and filters for the excitation and emission wavelengths specific for DAPI (excitation: 375 nm and emission: 435-480 nm) and NeonGreen (excitation: 488 nm and emission: 500-550 nm).

Primary drug screen analysis

Five fields per well were imaged and analysed using Harmony[®] (version 5.0). Screen data were analysed with the cellHTS2 R package.^{66,67} Raw measurements were scaled relative to the mean of the within-plate DMSO controls to report a percentage-of-control (PoC) for each feature and replicates were summarised as a median value. The replication between technical replicates was assessed using the Spearman correlation. Tibco Spotfire (version

14.0) software was used to process the large datasets. Hit determination was based on how the compounds compared against PoC in terms of infected and uninfected cells.

Animal experiments

All animal experiments were carried out in accordance with the UK Home Office regulations under the project licence PA780D61A and PP1321516 (from May 2024) and were approved by the Imperial College Animal Welfare and Ethical Review Body. Female, six- to seven-week-old C57BL/6 mice were purchased from Charles River Laboratories (Harlow, UK) and acclimatised for a week prior to cell injection. They had standard laboratory diet and free access to water. Mice were inoculated intraperitoneally (IP) with ID8 *Trp53*^{-/-} cells (5×10^6) in 200 μ l sterile PBS on day 0. The tumours were allowed to grow for 14, 21 or 28 days depending on the protocol of each study. Details of the experimental designs of these studies are provided in Figures 2, 5 and S1. Day 21 was used as the standard tumour establishment time point used in most *in vivo* survival studies, as it reflects late-stage disease. In the survival study presented in Figure S1, viral treatment began on day 14, and mice received four intraperitoneal (IP) viral injections instead of three. This modified protocol was designed to assess whether initiating treatment earlier, when tumour burden is lower, and increasing the number of viral doses could enhance therapeutic efficacy. Day 28 was used exclusively for the viral distribution study. This later time point was chosen to allow for greater tumour progression, providing larger tissue samples suitable for assessing viral localisation within the tumour. Sample sizes were established with the help of the experimental design assistant of NC3Rs to achieve statistical power while minimising animal use. All viruses were injected IP at a titre of 1×10^7 pfu/ml in 200 μ l sterile PBS. Vinorelbine tartrate was obtained from Hammersmith hospital pharmacy, Imperial Collage Healthcare NHS Trust (London, UK) and was injected IP at 4 mg/kg in 200 μ l sterile PBS. The mice were weighed daily, monitored regularly for adverse side effects, and were killed when reached humane endpoints. These included any of the following: swelling restricting movement, piloerection, hunched posture, reduced activity, facial grimace, dehydration lasting > 24 hours, 15% weight loss, altered respiration and self-mutilation. All decisions on animal welfare were made by staff blinded to treatment allocation. The schedule 1 method followed was cervical dislocation and exsanguination by decapitation. Omental tumours, liver and spleen were dissected and placed in 10% neutral buffered formalin for 48 hours and then transferred to 70% ethanol.

Histopathology

Harvested tissues, embedded in paraffin to create blocks, were sectioned at 3 µm thickness and attached on glass microscope slides for examination. Histochemical Haematoxylin and Eosin (H&E) staining was carried out using Tissue-Tek Prisma® Plus Automated Slide Stainer (Leica Biosystems, Deer Park, Illinois). Blinded histopathological analysis was performed by Professor Priestnall and Dr Suarez-Bonnet, board-certified veterinary pathologists associated with the Experimental Histopathology STP of The Francis Crick Institute. For immunohistochemistry (IHC), samples were stained for NeonGreen (1:200, Cell Signalling, #41236) and cleaved caspase 3 (1:250, Cell signalling, #9579S) antibodies, respectively. IHC staining was performed on the Leica Bond Rx autostainer platform (Leica Biosystems, #3498240) and a DAB kit which included a secondary antibody, DAB and haematoxylin counterstain was used (BOND Polymer Refine Detection, Leica Biosystems, #DS9800). The slides were scanned with a Zeiss Axio Scan Z1 Slide Scanner operated by ZEN Lite Software.

Quantitative analysis of immunohistochemistry slides was performed using QuPath (v0.3.0). Slides were scanned and imported from a secure server. Cell detection was carried out using default DAB channel parameters, matched to the chromogen used. Stain separation was optimised by estimating stain vectors. Tumour and non-tumour regions were annotated to train a random forest classifier for compartment classification. Cleaved caspase 3 and vaccinia staining were analysed using intensity thresholds of 0.15 and 0.2 respectively (Cell: DAB OD Mean). A script was developed to calculate the percentage of marker expression in tumour versus non-tumour areas, with results reported as intra-tumoural expression percentages.

Immunofluorescence

For fixed cell imaging, cells were seeded on 0.1% fibronectin-coated (Sigma-Aldrich, #F0895) coverslips. Cells were infected with vaccinia virus and at experimental endpoint, cells were fixed with 1ml of iced cold methanol for 20 minutes at -20°C and then washed with PBS. Cells were incubated in blocking buffer (1% bovine serum albumin and 2% fetal calf serum) for 30 minutes followed by the primary antibody for one hour. Primary antibodies used were as follows: B5 (1:1,000⁶⁸) and α - Tubulin (1:500, Sigma-Aldrich, #T6074). Cells were incubated in Alexa Fluor 488 and Alexa Fluor 568 conjugated secondary antibodies (1:1,000 dilution in blocking buffer) for a further 40 minutes and stained with DAPI (300 nM in PBS) for five minutes. Coverslips were mounted on glass

microscope slides using 5 µl Mowiol. Mounted coverslips were imaged on a Zeis Axio Observer spinning-disk microscope equipped with a Plan-Apochromat 100x/1.46 oil lens, an Evolve 512 camera and a Yokagawa CSUX spinning disk. The microscope was controlled by Slidebook software (3i Intelligent Imaging Innovations). Images were analysed using Fiji Imaging Analysis Software.

Live-cell imaging

ID8 *Trp53*^{-/-} cells were seeded at the desired confluency in 384-well plates and were transferred to the Incucyte S3 live-cell imaging system (Sartorius) to capture phase-contrast and green-fluorescent images every three hours using a 4x objective. Cells were removed from the Incucyte S3 at the required timepoints for drug treatment and/or infection and quickly replaced in the Incucyte to continue imaging. Whole wells were imaged and analysed using the integrated software module “Basic Analyser”. The median percentage confluency of infected and uninfected cells and the ratio of green fluorescence per well area were quantified. Raw data was exported for further statistical analysis.

Live cells to assess morphological changes following vinorelbine treatment were imaged using Invitrogen Evos™ M5000 microscope (Invitrogen) equipped with advanced LED illumination and a range of objective lenses to achieve various magnifications. Images were captured using the integrated software.

Statistical analysis

Statistical analysis was performed using Prism 10 (GraphPad Software). In all graphs, data are represented by the mean and standard deviations (SD) or median and interquartile range (IQR) from three independent experiments, unless stated otherwise. Data were tested for normality of distribution using normality and lognormality tests in Prism 10. For parametric data: Student’s t test was used to compare two data sets and one-way ANOVA for multiple data sets followed by either a Tukey’s (comparing samples to each other) or Dunnett’s (comparing samples to control) post hoc correction. For non-parametric data: Kruskal Wallis test for multiple data sets followed by Dunn’s post hoc test. P values < 0.05 were considered significant. For survival data, Kaplan Meier-survival analysis was used and log-rank Mantel-Cox test was applied to compare two or more survival curves. Pairwise comparisons of individual survival curves were performed manually, and a Bonferroni correction applied to determine the new threshold of significance.

Data availability statement

All data were stored on the internet server of The Francis Crick Institute and can be requested from the corresponding author.

Acknowledgments

This project was supported by Cancer Research UK (C422/A29942). M.W. is also supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (CC2096), the UK Medical Research Council (CC2096), and the Wellcome Trust (CC2096). I.A.M. also acknowledges support from Ovarian Cancer Action (grant number PSN418). For the purpose of open access, the authors have applied a CC BY public copyright licence to any author accepted manuscript version arising from this submission.

Author contributions

S.D. :Conceptualization, data curation, formal analysis, investigation, writing - original draft. **C.J.Q.** : Data curation, formal analysis, investigation, methodology, writing – review & editing. **K.E.T.** : *In vivo* investigation, methodology & validation. **L.A.S.** : Conceptualization, writing – review & editing. **A.P.** : Conceptualization, writing – review & editing. **I.D.R.** : Supervision, formal analysis, methodology, writing – review & editing. **D.P.E.** :Formal analysis **M.H.** :Supervision, resources, methodology. **I.A.M.** :Conceptualization, funding acquisition, resources, supervision, writing – review & editing. **M.W.** :Conceptualization, funding acquisition, resources, supervision, writing – review & editing.

Declarations of interests

The authors declare no competing interests.

Keywords

Vaccinia virus, oncolytic agent, combination therapies, ovarian cancer

Figure legends

Figure 1. Characterisation of recombinant vaccinia viruses

A. Immunoblot analysis comparing the expression levels of the indicated viral proteins in HeLa

cells infected with the specified viruses. Vinculin is the cell loading control. The experiment was repeated three times and a representative example is shown. **B.** Representative images of plaque formation by the indicated virus strains in BS-C-1 cells at 72 hpi. The graph represents quantitative analysis of plaque diameter measured in mm for the indicated viral strains. The three independent plaque assays are represented by the three different colours in the SuperPlot. Each dot represents one plaque, and the triangles represent the medians of all the plaques measured in each experiment. Data are represented as mean $\pm$ SD. One-way ANOVA was used to determine significance between all groups with Tukey multiple comparisons post-hoc test. **C.** Immunoblot analysis assessing PARP cleavage in ID8 *Trp53*^{-/-} cells infected with the indicated viruses. F12 and GRB2 represent viral and cell loading controls respectively. The asterisk (*) indicates a non-specific band. Hpi = hours post infection. The experiment was repeated three times and a representative blot is shown.

Figure 2. Efficacy of recombinant vaccinia viruses in vivo

A. Schematic representation of the experimental design of the *in vivo* survival study. Five groups of mice were injected IP with ID8 *Trp53*^{-/-} cells on day 0 and subsequently inoculated with the indicated viruses on day 21, 28 and 35. Δ VFi is the control heat inactivated virus. **B.** Kaplan-Meier survival curve showing survival data for each virus analysed by log-rank test. **C.** Quantification of omental tumour, spleen and liver weights as well as ascitic volumes for each group. Data are represented as mean $\pm$ SD. One-way ANOVA was used to determine significance between all groups with Tukey multiple comparisons post-hoc test.

Figure 3. Identifying targets for combination therapies with oncolytic vaccinia.

A. Schematic summarising the high throughput drug screening strategy. **B.** Representative images of ID8 *Trp53*^{-/-} cells infected with Δ VFTK-NG virus and treated with the indicated compounds belonging to the four categories. NeonGreen expression (green) indicates infected cells and DAPI was used to stain nuclei (blue). Cells were imaged using Opera Phenix Plus with 10x air objective. Scale bar = 200 μ m. **C.** Graphical illustration of compound allocation in the four categories. **D.** Representative graphs from the secondary validation screen of selected primary screen hits at 1 μ M (omipalisib, erlotinib and vinorelbine). The model represents an ideal compound and DMSO is the negative control. The purple dashed line represents the time at which Δ VFTK-NG virus (MOI 0.5) was added (16 hours post cell seeding). Statistical analysis was done by comparing uninfected against infected cell confluency at 20, 60 and 90 hours post cell seeding using Student's t-test. Error bars represent standard deviation (SD). **E.** List of hit compounds after the secondary validation screen.

Figure 4. Vaccinia and vinorelbine induces apoptotic ID8 *Trp53*^{-/-} cell death

A. Representative phase contrast images of ID8 *Trp53*^{-/-} cells after 16 hours treatment with DMSO or vinorelbine (1 μ M). Scale bar = 150 μ m. **B.** Immunofluorescent images of microtubule cytoskeleton (Tubulin - green) in ID8 *Trp53*^{-/-} cells treated with DMSO or vinorelbine with or without infection with Δ VFTK (Vaccinia - red). DAPI (blue) was used to stain nuclei and cytoplasmic viral factories. Yellow arrows indicate fragmented nuclei. Scale bar = 10 μ M. **C.** Immunoblot of the indicated viral proteins following infection for 4 or 8 hours with Δ VFTK-NG following 16 hours pre-treatment with DMSO or vinorelbine. Vinculin is the cell loading control. **D.** Immunoblot examining the levels of LC3 lipidation (LC3-II) and p62 in ID8 *Trp53*^{-/-} cells pretreated with vinorelbine or DMSO for 8 hours and infected with Δ VFTK-NG for 24 hours. Chloroquine (Clq) treatment for 3 hours represents the positive control. **E.** Immunoblot examining the levels of MLKL phosphorylation and PARP cleavage in ID8 *Trp53*^{-/-} cells pretreated with vinorelbine or DMSO for 8 hours and infected with Δ VFTK-NG for 24 hours. Staurosporine (S) (8 hours) and 0.1% hydrogen peroxide (H₂O₂) combined with Z-VAD (two hours) represent positive controls for apoptosis and necroptosis respectively. **F.** Immunoblot examining the levels of cleaved caspase 8, 3 and PARP in ID8 *Trp53*^{-/-} cells treated with vinorelbine 8 hours before or after infection with Δ VFTK-NG for 24 hours. In D, E and F H5 and GAPDH represent the viral and cell loading controls, respectively. For all experiments, uninfected DMSO-treated cells (UI) were the negative control. Asterisks (*) indicate non-specific bands. Immunoblot experiments were repeated three times and representative examples are shown. **G.** Median percentage cell confluency over time for the indicated conditions. Cells were treated with the indicated compounds or Δ VFTK-NG at 16 hours post seeding (dashed line numbered 1). The dashed line numbered 2 (24 hours post cell seeding) represents the time of addition of either vinorelbine or Δ VFTK-NG for the combination groups.

Figure 5. Assessing the efficacy of Δ VFTK-NG-GM-CSF in vivo

A. Schematic representation of the experimental design of the distribution study. Mice were injected IP with ID8 *Trp53*^{-/-} cells on day 0 and received their IP injection on day 28 and the combination groups received their second component (vinorelbine or virus) on day 29. Heat inactivated (HI) virus (Δ VFTK-NG-GM-CSFi) is the negative control. **B.** Quantification of viral DNA in omental tumour, liver and spleen measured by qPCR and expressed relative to viral DNA levels of the liver sample in the HI virus group. Error bars represent mean $\pm$ SD. **C.** Representative immunohistochemical images of the distribution of cleaved caspase 3 and NeonGreen in omental tumour, liver and spleen harvested from a mouse in Group 4. The graph shows the quantification of NeonGreen positive cells in omental tumours. **D.** Representative immunohistochemical images of the distribution of cleaved caspase 3 and NeonGreen in omental tumours from mice in Groups 1, 3 and 4. The graph shows the quantification of cleaved caspase 3 positive cells in omental tumours. **E.** Schematic

representation of the experimental design of the vaccinia-vinorelbine combination study. Mice were injected with ID8 *Trp53*^{-/-} cells on day 0 and started receiving their IP treatment injections on day 21. Mice allocated to single treatment groups received their inoculations on days 21, 28 and 35 and those allocated to the combination groups received vinorelbine and ΔVFTK-NG-GM-CSF 24 hours apart. Heat inactivated (HI) ΔVFTK-NG-GM-CSFi virus was the negative control. **F.** Kaplan-Meier survival curve showing survival data for each group analysed by log-rank test. One mouse belonging to group 2 was excluded from the analysis as after IP injection of ID8 *Trp53*^{-/-} cells omental tumour failed to form. The analysis is from the combination of two survival experiments following the same protocols.

741 **Table 1. List of 60 primary screen hits**

742

Drug	Mechanism of Action
2-amino-8-[4-(2-hydroxyethoxy) cyclohexyl]-6-(6-methoxy-3-pyridinyl)-4-methylpyrido[2,3-d]pyrimidin-7(8H)-one	PI3K/mTOR kinase inhibitor
5-Fluorouridine	Pyrimidine nucleoside analogue
Abexinostat	Pan-histone deacetylase inhibitor
Actinomycin	DNA repair inhibitor
Alvespimycin (17-DMAG) hydrochloride	HSP 90 inhibitor
Aminopterin	Dihydrofolate reductase inhibitor
Amsacrine hydrochloride	Topoisomerase II inhibitor
AT13387	HSP 90 inhibitor
Auristatin F	Tubulin polymerisation inhibitor
Bortezomib	Proteasome inhibitor
Canertinib	EGFR inhibitor
CCT137690	Aurora kinase inhibitor
Cephaeline	Emetic alkaloid
CH5138303	HSP 90 inhibitor
CHIR-124	Selective Chk1 inhibitor
Chromomycin A3	DNA replication and transcription inhibitor
Combretastatin A4	Tubulin polymerisation inhibitor
Cytarabine	Pyrimidine nucleoside analogue
Cytochalasin E	Actin polymerisation inhibitor
D8-MMAD	Tubulin polymerisation inhibitor
D8-MMAF hydrochloride	Tubulin polymerisation inhibitor
Diacetoxyscirpenol	Ribosome inhibitor
Diosgenin	Precursor of steroidal hormones
Dp44mT	Iron chelator
Ellipticine	Topoisomerase II inhibitor
Emetine hydrochloride hydrate	Ribosome inhibitor
Enzastaurin	Protein kinase C inhibitor
Erastin	Ferroptosis inducer
Ergosterol	Sterol
Floxuridine	Pyrimidine nucleoside analogue
Fosbretabulin disodium	Tubulin polymerisation inhibitor
Ganetespib	HSP90 inhibitor
Geldanamycin	HSK90 inhibitor
Gemcitabine	Nucleoside (cytidine analogue) metabolic inhibitor
GSK3787	PPAR δ antagonist
HSP990	HSP90 inhibitor
Imidazole ketone erastin	Ferroptosis inducer
MMAD	Tubulin polymerisation inhibitor
MMAF hydrochloride	Tubulin polymerisation inhibitor
MMAF-OMe	ADC cytotoxin and tubulin polymerisation inhibitor
NSC319726	p53 ^{R175} mutant reactivator
Nutlin-3	P53-MDM2 interaction inhibitor
NVP-TAE226	Focal adhesion kinase inhibitor
Pazopanib hydrochloride	Protein tyrosine kinase inhibitor
PDGF receptor tyrosine kinase inhibitor IV	Tyrosine kinase inhibitor
Premetrexed	Folate-dependent enzyme inhibitor. Inhibitor of nucleotide synthesis
Podophyllotoxin	Tubulin polymerisation inhibitor
Pralatrexate	Dihydrofolate reductase inhibitor
PU-H71	HSP90 inhibitor
Raltitrexed	Thymidylate synthase inhibitor
Rosiglitazone	PPAR agonist
Silvestrol	RNA helicase inhibitor
Tanespimycin	HSP90 inhibitor
Thapsigargin	Sarco-endoplasmic reticulum Ca ²⁺ ATPase inhibitor
TRAM-34	Potassium Channel inhibitor
Trifluridine	Nucleoside metabolic inhibitor
Tubulin inhibitor 1	Tubulin polymerisation inhibitor
Vinblastine	Tubulin polymerisation inhibitor
Vincristine sulfate	Tubulin polymerisation inhibitor
Vinorelbine	Tubulin polymerisation inhibitor

References

1. CRUK. (2019). Cancer Research UK, Ovarian cancer survival statistics. <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/survival#ref-> Last accessed: June 2024
2. De Leo, A., Santini, D., Ceccarelli, C., Santandrea, G., Palicelli, A., Acquaviva, G., Chiarucci, F., Rosini, F., Ravegnini, G., Pession, A., et al. (2021). What Is New on Ovarian Carcinoma: Integrated Morphologic and Molecular Analysis Following the New 2020 World Health Organization Classification of Female Genital Tumors. *Diagnostics (Basel)* 11(4): 697.
3. González-Martín, A., Harter, P., Leary, A., Lorusso, D., Miller, R.E., Pothuri, B., Ray-Coquard, I., Tan, D.S.P., Bellet, E., Oaknin, A., et al. (2023). Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 34(10): 833-848.
4. Pokhriyal, R., Hariprasad, R., Kumar, L. and Hariprasad, G. (2019). Chemotherapy Resistance in Advanced Ovarian Cancer Patients. *Biomark Cancer* 11: 1179299x19860815.
5. Haunschild, C.E. and Tewari, K.S. (2020). Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer. *Future Oncol* 16(7): 225-246.
6. Konstantinopoulos, P.A., Norquist, B., Lacchetti, C., Armstrong, D., Grisham, R.N., Goodfellow, P.J., Kohn, E.C., Levine, D.A., Liu, J.F., Lu, K.H., et al. (2020). Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. *J Clin Oncol* 38(11): 1222-1245.
7. Vasan, N., Baselga, J. and Hyman, D.M. (2019). A view on drug resistance in cancer. *Nature* 575(7782): 299-309.
8. Wang, L., Wang, X., Zhu, X., Zhong, L., Jiang, Q., Wang, Y., Tang, Q., Li, Q., Zhang, C., Wang, H., et al. (2024). Drug resistance in ovarian cancer: from mechanism to clinical trial. *Mol Cancer* 23(1): 66.
9. Zhao, Y., Adams, Y.F. and Croft, M. (2011). Preferential replication of vaccinia virus in the ovaries is independent of immune regulation through IL-10 and TGF-beta. *Viral Immunol* 24(5): 387-396.
10. Fenner, F., Hendersan, D.A., Arita, I., Jezek, Z. and Ladnyi, I.D. (1988). Smallpox and its eradication, World Health Organisation.
11. Yu, Y.A., Shabahang, S., Timiryasova, T.M., Zhang, Q., Beltz, R., Gentshev, I., Goebel, W. and Szalay, A.A. (2004). Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins. *Nat Biotechnol* 22(3): 313-320.
12. Bell, J. and McFadden, G. (2014). Viruses for tumor therapy. *Cell Host Microbe* 15(3): 260-265.

13. Zhang, S. and Rabkin, S.D. (2021). The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? *Expert Opin Drug Discov* 16(4): 391-410.
14. Moss, B. (2013). Poxvirus DNA replication. *Cold Spring Harb Perspect Biol* 5(9): a010199.
15. Guo, Z.S., Lu, B., Guo, Z., Giehl, E., Feist, M., Dai, E., Liu, W., Storkus, W.J., He, Y., Liu, Z., et al. (2019). Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. *J Immunother Cancer* 7(1): 6.
16. Buller, R.M., Smith, G.L., Cremer, K., Notkins, A.L. and Moss, B. (1985). Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. *Nature* 317(6040): 813-815.
17. McCart, J.A., Ward, J.M., Lee, J., Hu, Y., Alexander, H.R., Libutti, S.K., Moss, B. and Bartlett, D.L. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. *Cancer Res* 61(24): 8751-8757.
18. Byrd, C.M. and Hruby, D.E. (2004). Construction of Recombinant Vaccinia Virus. *Vaccinia Virus and Poxvirology: Methods and Protocols*. S. N. Isaacs. Totowa, NJ, Humana Press: 31-40.
19. Zhang, Z., Dong, L., Zhao, C., Zheng, P., Zhang, X. and Xu, J. (2021). Vaccinia virus-based vector against infectious diseases and tumors. *Hum Vaccin Immunother* 17(6): 1578-1585.
20. Smith, G.L. and Moss, B. (1983). Infectious poxvirus vectors have capacity for at least 25 000 base pairs of foreign DNA. *Gene* 25(1): 21-28.
21. Chiocca, E.A. and Rabkin, S.D. (2014). Oncolytic viruses and their application to cancer immunotherapy. *Cancer Immunol Res* 2(4): 295-300.
22. Kaufman, H.L., Kohlhapp, F.J. and Zloza, A. (2015). Oncolytic viruses: a new class of immunotherapy drugs. *Nat Rev Drug Discov* 14(9): 642-662.
23. Holloway, R.W., Mendivil, A.A., Kendrick, J.E., Abaid, L.N., Brown, J.V., LeBlanc, J., McKenzie, N.D., Mori, K.M. and Ahmad, S. (2023). Clinical Activity of Olvimulogene Nanivacirepvec—Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory Ovarian Cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial. *JAMA Oncol* 9(7): 903-908.
24. Holloway, R.W., Thaker, P., Mendivil, A.A., Ahmad, S., Al-Niaimi, A.N., Barter, J., Beck, T., Chambers, S.K., Coleman, R.L., Crafton, S.M., et al. (2023). A phase III, multicenter, randomized study of olvimulogene nanivacirepvec followed by platinum-doublet chemotherapy and bevacizumab compared with platinum-doublet chemotherapy and bevacizumab in women with platinum-resistant/refractory ovarian cancer. *Int J Gynecol Cancer* 33(9): 1458-1463.
25. Michael, A., Wilson, W., Sunshine, S., Annels, N., Harrop, R., Blount, D., Pandha, H., Lord, R., Ngai, Y., Nicum, S., et al. (2024). A randomized phase II trial to examine modified vaccinia

817 Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC). *Int J*
818 *Gynecol Cancer* 34(8): 1225-1231.

819 26. Wasilenko, S.T., Banadyga, L., Bond, D. and Barry, M. (2005). The vaccinia virus F1L
820 protein interacts with the proapoptotic protein Bak and inhibits Bak activation. *J Virol* 79(22):
821 14031-14043.

822 27. Postigo, A., Cross, J.R., Downward, J. and Way, M. (2006). Interaction of F1L with the
823 BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. *Cell Death Differ*
824 13(10): 1651-1662.

825 28. Blomquist, M.C., Hunt, L.T. and Barker, W.C. (1984). Vaccinia virus 19-kilodalton protein:
826 relationship to several mammalian proteins, including two growth factors. *Proc Natl Acad Sci*
827 *U S A* 81(23): 7363-7367.

828 29. Brown, J.P., Twardzik, D.R., Marquardt, H. and Todaro, G.J. (1985). Vaccinia virus
829 encodes a polypeptide homologous to epidermal growth factor and transforming growth factor.
830 *Nature* 313(6002): 491-492.

831 30. Postigo, A., Martin, M.C., Dodding, M.P. and Way, M. (2009). Vaccinia-induced epidermal
832 growth factor receptor-MEK signalling and the anti-apoptotic protein F1L synergize to
833 suppress cell death during infection. *Cell Microbiol* 11(8): 1208-1218.

834 31. Gregory, R.K. and Smith, I.E. (2000). Vinorelbine--a clinical review. *Br J Cancer* 82(12):
835 1907-1913.

836 32. Banyal, A., Tiwari, S., Sharma, A., Chanana, I., Patel, S.K.S., Kulshrestha, S. and Kumar,
837 P. (2023). Vinca alkaloids as a potential cancer therapeutics: recent update and future
838 challenges. *3 Biotech* 13(6): 211.

839 33. Galano, G., Caputo, M., Tecce, M.F. and Capasso, A. (2011). Efficacy and tolerability of
840 vinorelbine in the cancer therapy. *Curr Drug Saf* 6(3): 185-193.

841 34. Barletta, G., Genova, C., Rijavec, E., Burrafato, G., Biello, F., Sini, C., Dal Bello, M.G.,
842 Coco, S., Truini, A., Vanni, I., et al. (2014). Oral vinorelbine in the treatment of non-small-cell
843 lung cancer. *Expert Opin Pharmacother* 15(11): 1585-1599.

844 35. Sørensen, P., Høyer, M., Jakobsen, A., Malmström, H., Havsteen, H. and Bertelsen, K.
845 (2001). Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
846 *Gynecol Oncol* 81(1): 58-62.

847 36. Rothenberg, M.L., Liu, P.Y., Wilczynski, S., Nahhas, W.A., Winakur, G.L., Jiang, C.S.,
848 Moinpour, C.M., Lyons, B., Weiss, G.R., Essell, J.H., et al. (2004). Phase II trial of vinorelbine
849 for relapsed ovarian cancer: a Southwest Oncology Group study. *Gynecol Oncol* 95(3): 506-
850 512.

851 37. Yeon, S.H., Lee, M.W., Ryu, H., Song, I.C., Yun, H.J., Jo, D.Y., Ko, Y.B. and Lee, H.J.
852 (2023). Efficacy of cisplatin combined with vinorelbine as second- or higher-line palliative

chemotherapy in patients with advanced ovarian cancer. *Medicine (Baltimore)* 102(11): e33271.

38. NICE. (2024). Vinorelbine. Last accessed: September 2024

39. Rietdorf, J., Ploubidou, A., Reckmann, I., Holmström, A., Frischknecht, F., Zettl, M., Zimmermann, T. and Way, M. (2001). Kinesin-dependent movement on microtubules precedes actin-based motility of vaccinia virus. *Nat Cell Biol* 3(11): 992-1000.

40. Dodding, M.P. and Way, M. (2011). Coupling viruses to dynein and kinesin-1. *EMBO J* 30(17): 3527-3539.

41. Leite, F. and Way, M. (2015). The role of signalling and the cytoskeleton during Vaccinia Virus egress. *Virus Res* 209: 87-99.

42. Xu, A., Basant, A., Schleich, S., Newsome, T.P. and Way, M. (2023). Kinesin-1 transports morphologically distinct intracellular virions during vaccinia infection. *J Cell Sci* 136(5): jcs260175.

43. Ploubidou, A., Moreau, V., Ashman, K., Reckmann, I., González, C. and Way, M. (2000). Vaccinia virus infection disrupts microtubule organization and centrosome function. *EMBO J* 19(15): 3932-3944.

44. Gobeil, S., Boucher, C.C., Nadeau, D. and Poirier, G.G. (2001). Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. *Cell Death Differ* 8(6): 588-594.

45. Kaufmann, S.H., Desnoyers, S., Ottaviano, Y., Davidson, N.E. and Poirier, G.G. (1993). Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. *Cancer Res* 53(17): 3976-3985.

46. Mirbahari, S.N., Da Silva, M., Zúñiga, A.I.M., Kooshki Zamani, N., St-Laurent, G., Totonchi, M. and Azad, T. (2024). Recent progress in combination therapy of oncolytic vaccinia virus. *Front Immunol* 15: 1272351.

47. Xu, L., Sun, H., Lemoine, N.R., Xuan, Y. and Wang, P. (2024). Oncolytic vaccinia virus and cancer immunotherapy. *Front Immunol* 14: 1324744.

48. Buller, R.M., Chakrabarti, S., Cooper, J.A., Twardzik, D.R. and Moss, B. (1988). Deletion of the vaccinia virus growth factor gene reduces virus virulence. *J Virol* 62(3): 866-874.

49. Pelin, A., Foloppe, J., Petryk, J., Singaravelu, R., Hussein, M., Gossart, F., Jennings, V.A., Stubbert, L.J., Foster, M., Storbeck, C., et al. (2019). Deletion of Apoptosis Inhibitor F1L in Vaccinia Virus Increases Safety and Oncolysis for Cancer Therapy. *Mol Ther Oncolytics* 14: 246-252.

50. Haddad, D. and Fong, Y. (2015). Molecular imaging of oncolytic viral therapy. *Mol Ther Oncolytics* 1: 14007.

51. Concilio, S.C., Russell, S.J. and Peng, K.W. (2021). A brief review of reporter gene imaging in oncolytic virotherapy and gene therapy. *Mol Ther Oncolytics* 21: 98-109.

52. Rieder, C.L. and Maiato, H. (2004). Stuck in Division or Passing through: What Happens When Cells Cannot Satisfy the Spindle Assembly Checkpoint. *Dev Cell* 7(5): 637-651.
53. Bates, D. and Eastman, A. (2017). Microtubule destabilising agents: far more than just antimitotic anticancer drugs. *Br J Clin Pharmacol* 83(2): 255-268.
54. Rovini, A., Savry, A., Braguer, D. and Carré, M. (2011). Microtubule-targeted agents: when mitochondria become essential to chemotherapy. *Biochim Biophys Acta* 1807(6): 679-688.
55. Whitaker, R.H. and Placzek, W.J. (2019). Regulating the BCL2 Family to Improve Sensitivity to Microtubule Targeting Agents. *Cells* 8(4): 346.
56. Wordeman, L. and Vicente, J.J. (2021). Microtubule Targeting Agents in Disease: Classic Drugs, Novel Roles. *Cancers* 13(22): 5650.
57. Ni Chonghaile, T., Sarosiek, K.A., Vo, T.T., Ryan, J.A., Tammareddi, A., Moore Vdel, G., Deng, J., Anderson, K.C., Richardson, P., Tai, Y.T., et al. (2011). Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. *Science* 334(6059): 1129-1133.
58. Arulanandam, R., Batenchuk, C., Varette, O., Zakaria, C., Garcia, V., Forbes, N.E., Davis, C., Krishnan, R., Karmacharya, R., Cox, J., et al. (2015). Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. *Nat Commun* 6: 6410.
59. Armstrong, D.K., Alvarez, R.D., Backes, F.J., Bakkum-Gamez, J.N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L.M., Chitiyo, V.C., Cristea, M., et al. (2022). NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022. *J Natl Compr Canc Netw* 20(9): 972-980.
60. Walton, J., Blagih, J., Ennis, D., Leung, E., Dowson, S., Farquharson, M., Tookman, L.A., Orange, C., Athineos, D., Mason, S., et al. (2016). CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. *Cancer Res* 76(20): 6118-6129.
61. Falkner, F.G. and Moss, B. (1990). Transient dominant selection of recombinant vaccinia viruses. *J Virol* 64(6): 3108-3111.
62. Wong, Y.C., Lin, L.C., Melo-Silva, C.R., Smith, S.A. and Tscharke, D.C. (2011). Engineering recombinant poxviruses using a compact GFP-blasticidin resistance fusion gene for selection. *J Virol Methods* 171(1): 295-298.
63. Schmittgen, T.D. and Livak, K.J. (2008). Analyzing real-time PCR data by the comparative C(T) method. *Nat Protoc* 3(6): 1101-1108.
64. Dodding, M.P., Newsome, T.P., Collinson, L.M., Edwards, C. and Way, M. (2009). An E2-F12 complex is required for intracellular enveloped virus morphogenesis during vaccinia infection. *Cell Microbiol* 11(5): 808-824.

926 65. Tolonen, N., Doglio, L., Schleich, S. and Krijnse Locker, J. (2001). Vaccinia virus DNA
927 replication occurs in endoplasmic reticulum-enclosed cytoplasmic mini-nuclei. *Mol Biol Cell*
928 12(7): 2031-2046.

929 66. Boutros, M., Brás, L.P. and Huber, W. (2006). Analysis of cell-based RNAi screens.
930 *Genome Biol* 7(7): R66.

931 67. Boutros, M., Brás, L.P. and Huber, W. (2023). End-to-end analysis of cell-based screens:
932 from raw intensity readings to the annotated hit list.
933 [https://bioconductor.org/packages/release/bioc/vignettes/cellHTS2/inst/doc/cellhts2Complete](https://bioconductor.org/packages/release/bioc/vignettes/cellHTS2/inst/doc/cellhts2Complete.pdf)
934 [.pdf](https://bioconductor.org/packages/release/bioc/vignettes/cellHTS2/inst/doc/cellhts2Complete.pdf) Last accessed: April 2024

935 68. Schmelz, M., Sodeik, B., Ericsson, M., Wolffe, E.J., Shida, H., Hiller, G. and Griffiths, G.
936 (1994). Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans
937 Golgi network. *J Virol* 68(1): 130-147.

938




Figure 1





Figure 2






Figure 4

Figure 5

Click here to access/download;Figure (high resolution without caption);Figure 5 revised final.pdf




Figure 5




Figure S1. $\Delta VFTK-NG-GM-CSF$ provides superior survival benefit in monotherapy
A. Schematic representation of the experimental design of the *in vivo* survival study. Four groups of mice were injected IP with ID8 *Trp53*^{-/-} cells on day 0 and subsequently inoculated with the indicated viruses on day 14, 21, 28 and 35. ΔVFi is the control heat inactivated virus. **B.** Kaplan-Meier survival curve showing survival data for each virus analysed by log-rank test. **C.** Quantification of omental tumour, spleen and liver weights as well as ascitic volumes for each group. Data are represented as mean $\pm$ SD. One-way ANOVA was used to determine significance between all groups with Tukey multiple comparisons post-hoc test.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24
A	DMSO	DMSO	AG-1478	Ellipticine (hydrochloride)	TM66-34	Nolatrexed dihydrochloride	Sliglaplin	MM45-One	Emectrapib	Eradin	Ceftriaxime	MM40	Enasclarin	Cyclochalatan E	TPCA-1	Amisuglerin	MD-0354	DMSO	Seprantrium (bromide)	DMSO	Olaparib	DMSO	DMSO	DMSO
B	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
C	DMSO	DMSO	Gencitabine	Gedaretinib	Iniparib	Idamustin	Finasteride	SMC-2112	Chromomycin A3	MM45 (hydrochloride)	CCT-137690	DMSO	Methotrexate	DMSO	Abiraterone (hydrochloride)	Penicillate (sodium)	Cabozantinib	DMSO	Pralatrexate	DMSO	Sunitinib (succinate)	DMSO	DMSO	DMSO
D	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
E	DMSO	DMSO	Bortezomib	Harringtonine	Mitoxantrone	AMG131	GW42166X	Indazole lactone Grazatinib	PF-573228	Thapsigargin	NSC319726	DMSO	Raltitrexed	DMSO	Ompalalib	Uricloacillin (sodium hydrate)	CHR-124	DMSO	Vincetibine (succinate)	DMSO	Erlotinib	DMSO	DMSO	DMSO
F	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
G	DMSO	DMSO	Clofazimine	Trifluoridine	Tolnate	Combretastatin A4	Almaladine (hydrochloride)	Auristatin F	JNJ-42165279	PU-H71	Fluorocillin sodium	DMSO	Onalespib	DMSO	Venizostat	DMSO	GSK2334470	TUG-469	DMSO	CCT241736	DMSO	DMSO	DMSO	DMSO
H	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
I	DMSO	DMSO	Ruboxistaurin	NVP-2	Doxastereide	Prexasertib	Daunorubicin (hydrochloride)	Ronapenide	LY292470	WR99210	Anasacrine (hydrochloride)	Expedicel	Roniglitazone	DMSO	AT7519	DMSO	Casertinib (dihydrochloride)	Fasiglitam	DMSO	Nutlin-3a	DMSO	DMSO	DMSO	DMSO
J	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
K	DMSO	DMSO	Tanespimycin	BRL-54443	Ganetespib	Podofilox	GSK2787	Alcristostat	SNS-432	Ceritinib	Elaclamol	2518474	MA-0204	DMSO	BR795	DMSO	Tubulin inhibitor 1	Torcetrapib	DMSO	JNJ-10190409	DMSO	DMSO	DMSO	DMSO
L	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
M	DMSO	DMSO	Rotlumilast	Glactoxipropene 1	Cytarabine	NVP-H9990	Trimastix (maleate)	Silvestrol	Apremilast	Nonectin	CP-91149	F118	Cetuximab	DMSO	Floxuridine	DMSO	(R)-CR8	NVP-TAE 226	DMSO	Alogliptin	DMSO	DMSO	DMSO	DMSO
N	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO
O	DMSO	DMSO	PF-3845	CP-316819	Bay 59-3074	Diquemib	Vindesine (sulfate)	Alciglar	Seratinib	SP10-DM4	Pazopanib (hydrochloride)	OT518303	5-Fluorouridine	DMSO	Vinblastine (sulfate)	DMSO	PF-04691502	PS-1145	DMSO	Dinacilicb	DMSO	DMSO	DMSO	DMSO
P	DMSO	DMSO		DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO	DMSO

Solvent Water

Solvent Ethanol

Solvent DMSO

Red: 2 mM concentration

Black: 10 mM concentration

Figure S2. Secondary screen mother plate layout

OVCA3

- Inhibitor-treated (uninfected) cell confluency
- Infected and inhibitor-treated cell confluency
- NeonGreen area:cell area ratio




Figure S3. Tubulin assembly inhibitors enhance vaccinia-induced OVCAR3 cell death
Representative graphs of the combination of the indicated tubulin polymerisation inhibitors with vaccinia in OVCAR3 cell line. The purple dotted line represents infection with Δ VFTK-NG (MOI 0.5) at 18 hours post cell seeding. All compounds were used at 1 μ M. Student's t-test was used to compare uninfected against infected cell confluency at 25, 60 and 90 hours post cell seeding. Error bars represent SD.




Figure S4. Tubulin assembly inhibitors enhance vaccinia-induced OVCAR4 cell death
 Representative graphs of the combination of the indicated tubulin polymerisation inhibitors with vaccinia in OVCAR4 cell line. The purple dotted line represents infection with Δ VFTK-NG (MOI 0.5) at 18 hours post cell seeding. All compounds were used at 1 μ M. Student's t-test was used to compare uninfected against infected cell confluency at 25, 60 and 90 hours post cell seeding. Error bars represent SD. 4




Figure S5. Quantification of GM-CSF mRNA in Δ VFTK-NG-GM-CSF infected tumours
 Quantification of GM-CSF mRNA in omental tumours infected with virus (Δ VFTK-NG-GM-CSF) with or without vinorelbine treatment. HI represents the heat inactivated control virus control. The tumour samples are from the same experiments shown in Figure 5A. Error bars represent mean $\pm$ SD.

VACWR009	VACWR040		VACWR094		VACWR210		Gene name
VGF		F1		TK		VGF	Western Reserve
VGF		F1		TK		VGF	Δ VF (Δ VGF/ Δ F1)
VGF		F1		TK		VGF	Δ VFTK (Δ VGF/ Δ F1/ Δ TK)
VGF		F1		NG		VGF	Δ VFTK-NG (Δ VGF/ Δ F1/ Δ TK-expressing NG)
VGF		F1		NG-GM-CSF		VGF	Δ VFTK-NG (Δ VGF/ Δ F1/ Δ TK-expressing NG-GM-CSF)

Figure S6. Generation of recombinant viruses
Schematic illustrating the gene modifications made for the generation if the indicated recombinant viruses